Gilead Sciences, Inc.

1507 articles with Gilead Sciences, Inc.

• Gilead Announces Latest Data in Ongoing HIV Cure Research Program

  7/23/2019

  Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program

• Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

  7/22/2019

  Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function.

• Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance

  7/22/2019

  Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets

• DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

  7/22/2019

  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology

• 

  DURECT and Gilead Collaborate on HIV Therapy in Potential $320 Million+ Deal

  7/22/2019

  “We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.

• Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

  7/19/2019

  Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.

• 

  Roche and Novo Nordisk Top Clinical Trial Transparency Survey

  7/19/2019

  In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
• 

  Gilead Snaps up Antiviral Programs From Novartis, Follows Slew of Other Pipeline-Bolstering Deals

  7/19/2019

  In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
• 

  BioSpace Movers and Shakers, July 19

  7/19/2019

  Pharma and biotech companies from across the globe expand their leadership teams and boards.

• Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019

  7/18/2019

  Fifteen abstracts, along with community-focused symposia and workshops, reflect Gilead’s ongoing commitment to scientific innovation, a key pillar to addressing unmet and evolving medical needs in HIV.

• Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company

  7/17/2019

  The company will immediately commence a search for his successor.

• Gilead Sciences Announces Changes to Senior Leadership Team

  7/17/2019

  Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.

• 

  Gilead CSO, Other Executives, Departing Company as CEO Continues to Reshape C-Suite

  7/17/2019

  Daniel O'Day took over the reins of Gilead Sciences in March and has been building his team of lieutenants.

• AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs

  7/17/2019

  AIDS Healthcare Foundation (AHF) is calling on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, to set up a $10 billion victim compensation fund for patients harmed after taking the drug maker’s TDF-based (tenofovir disoproxil fumarate) drugs as part of their treatment for HIV or AIDS or taken by uninfected individuals as part of the HIV prevention strategy known as pre-exposure prophylaxis or PrEP.

• Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

  7/16/2019

  Kite, a Gilead Company, announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.

• Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

  7/16/2019

  The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/.

• CORRECTING and REPLACING Alcoholic Hepatitis Treatment Market Worth USD 570 Million, at 6% CAGR during 2019-2023 | Technavio

  7/16/2019

  According to Technavio Research Report "Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others), and geographic regions (North America, Europe, Asia, and ROW) is witnessed to grow by USD 570 million, at a CAGR of 6% from 2019 to 2023”.

• 

  Gilead Increases Stake in Galapagos with 10-Year Deal Worth More than $5 Billion

  7/15/2019

  Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos' pipeline.
• 

  Clinical Catch-Up for July 8-12

  7/15/2019

  It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.

• Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

  7/14/2019

  Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.